# AMT Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amt-medical

- Industry: Medical Devices & Equipment
- Headquarters: Netherlands
- Website: www.amt-medical.nl/
- Total disclosed funding: $25M
- Latest round: Series B (Apr 15, 2025)
- Investors on record: 3

## About

AMT Medical BV is a Netherlands-based medical device company focused on enhancing coronary artery bypass surgery through innovative technology.Founded in 2015 in the Netherlands, AMT Medical BV specializes in developing advanced solutions for coronary artery bypass procedures. The company has remained focused on its flagship product, the Elana Heart Bypass System, without significant pivots in its business strategy. The founder's specific background is not publicly detailed, and the company does not have reported subsidiaries. 

AMT Medical has successfully raised a total of EUR 22.00 mn through its latest funding round, a Series B round, completed on April 15, 2025. This round was led by European Innovation Council, Invest-NL, and Oost NL, with participation from additional investors.AMT Medical specializes in the development of its flagship product, the Elana Heart Bypass System, which revolutionizes coronary artery bypass surgery. The Elana system utilizes advanced technology, including a uniquely designed Heart Clip and Heart Laser Catheter, enabling minimally invasive procedures. Surgeons can perform bypass surgery through small chest incisions, eliminating the need for heart stoppage and heart-lung machines, thereby reducing recovery times and risks. The key end users of the Elana system are hospitals and surgical centers treating patients with coronary artery disease, primarily targeting markets in Europe and North America.The revenue model for AMT Medical is based on direct sales of the Elana Heart Bypass System to healthcare institutions. Transactions are structured around B2B relationships, where hospitals and surgical centers purchase the Elana system and its components for surgical use. Clients often enter agreements for bulk purchases or long-term supply contracts, ensuring the consistent availability of the Elana system, with pricing reflecting the advanced technology of the product, in line with healthcare standards for medical devices.AMT Medical plans to utilize the EUR 22.00 mn raised in its Series B funding to support significant initiatives, including CE marking and early clinical trials in both open and robotic settings in the US. The company aims to expand its reach into new markets, particularly focusing on the US by the end of 2025, while also working on upcoming product developments to enhance its Elana Heart Bypass System.

## Funding rounds

- Series B, Apr 15, 2025, $25M — Oost NL, European Innovation Council, Invest-NL

## Investors

- Oost NL (https://capitalatlas.ai/funds/oost-nl) — Series B
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series B
- Invest-NL — Series B